Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

TAP to develop xanthine oxidase inhibitor from Teijin in North America

Oct. 7, 1999

Searle presents new series of potent and selective vitronectin receptor antagonists

Oct. 7, 1999

ASBMR news: preclinical and clinical studies support efficacy, safety of Amgen's OPG

Oct. 7, 1999

Dual glucagon antagonists/cytokine inhibitors in the Merck pipeline

Oct. 7, 1999

Ares-Serono files for approval of new infertility treatment

Oct. 7, 1999

Meta-analysis establishes higher pregnancy rates with rFSH than with uFSH

Oct. 7, 1999

Dompe identifies lead tartronate derivative for development as antiosteopenic agent

Oct. 7, 1999

TheraTech and Procter & Gamble rework agreements for female HRT products

Oct. 6, 1999

TAK-778, the first nonendogenous compound able to promote new bone formation and heal breaks

Oct. 6, 1999

Potent and selective vitronectin antagonists developed at SmithKline Beecham

Oct. 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...